Tags

Type your tag names separated by a space and hit enter

Multiple sclerosis symptoms and spasticity management: new data.
Neurodegener Dis Manag. 2017 Nov; 7(6s):7-11.ND

Abstract

Spasticity, perceived by patients as muscle rigidity and spasms, is a common symptom in multiple sclerosis (MS). It is associated with functional impairment that can exacerbate other MS symptoms and reduce quality of life. Pharmacological treatment options are limited and frequently ineffective. Treatment adherence is a key issue to address in these patients. The efficacy and safety of 9-delta-tetrahydrocannabinol:cannabidiol (THC:CBD) oromucosal spray for treatment of MS spasticity were demonstrated in four Phase III trials. Observational studies and registry data subsequently confirmed the effectiveness and tolerability of THC:CBD oromucosal spray under everyday practice conditions. Among patients who respond to treatment, THC:CBD oromucosal spray has been shown to produce positive improvements in gait parameters and to normalize muscle fibers.

Authors+Show Affiliations

Department of Neurology, Hospital Universitario Virgen Macarena, Avenida Doctor Fedriani, 3, 41009, Seville, Spain.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29143581

Citation

Izquierdo, Guillermo. "Multiple Sclerosis Symptoms and Spasticity Management: New Data." Neurodegenerative Disease Management, vol. 7, no. 6s, 2017, pp. 7-11.
Izquierdo G. Multiple sclerosis symptoms and spasticity management: new data. Neurodegener Dis Manag. 2017;7(6s):7-11.
Izquierdo, G. (2017). Multiple sclerosis symptoms and spasticity management: new data. Neurodegenerative Disease Management, 7(6s), 7-11. https://doi.org/10.2217/nmt-2017-0034
Izquierdo G. Multiple Sclerosis Symptoms and Spasticity Management: New Data. Neurodegener Dis Manag. 2017;7(6s):7-11. PubMed PMID: 29143581.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multiple sclerosis symptoms and spasticity management: new data. A1 - Izquierdo,Guillermo, PY - 2017/11/17/entrez PY - 2017/11/17/pubmed PY - 2018/6/26/medline KW - THC:CBD oromucosal spray KW - multiple sclerosis KW - spasticity management SP - 7 EP - 11 JF - Neurodegenerative disease management JO - Neurodegener Dis Manag VL - 7 IS - 6s N2 - Spasticity, perceived by patients as muscle rigidity and spasms, is a common symptom in multiple sclerosis (MS). It is associated with functional impairment that can exacerbate other MS symptoms and reduce quality of life. Pharmacological treatment options are limited and frequently ineffective. Treatment adherence is a key issue to address in these patients. The efficacy and safety of 9-delta-tetrahydrocannabinol:cannabidiol (THC:CBD) oromucosal spray for treatment of MS spasticity were demonstrated in four Phase III trials. Observational studies and registry data subsequently confirmed the effectiveness and tolerability of THC:CBD oromucosal spray under everyday practice conditions. Among patients who respond to treatment, THC:CBD oromucosal spray has been shown to produce positive improvements in gait parameters and to normalize muscle fibers. SN - 1758-2032 UR - https://www.unboundmedicine.com/medline/citation/29143581/Multiple_sclerosis_symptoms_and_spasticity_management:_new_data_ L2 - http://www.futuremedicine.com/doi/full/10.2217/nmt-2017-0034?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -